Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

BACKGROUND: We evaluated the efficacy and safety of the aromatase inhibitor exemestane in patients with advanced, persistent or recurrent endometrial carcinoma. METHODS: We performed an open-label one-arm, two-stage, phase II study of 25 mg of oral exemestane in 51 patients with advanced (FIGO stage...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindemann, Kristina, Malander, Susanne, Christensen, Rene D, Mirza, Mansoor R, Kristensen, Gunnar B, Aavall-Lundqvist, Elisabeth, Vergote, Ignace, Rosenberg, Per, Boman, Karin, Nordstrøm, Britta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924910/
https://www.ncbi.nlm.nih.gov/pubmed/24498853
http://dx.doi.org/10.1186/1471-2407-14-68

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924910/
https://www.ncbi.nlm.nih.gov/pubmed/24498853
http://dx.doi.org/10.1186/1471-2407-14-68

Ejemplares similares